A Phase 3 interventional study of Finerenone (Kerendia, BAY94-8862) and Placebo in Left Ventricular Systolic Dysfunction and Heart Failure (Pediatric), sponsored by Bayer. Recruiting at 133 sites in 23 countries. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Ventricular Dysfunction, Left with a site in United States — 15 open to participants now, 21 under way, 3 of them phase 3. Ventricular Dysfunction, Left · United States.
Among the 84 studies in Ventricular Dysfunction, Left with a site in United States, this one is the 22nd largest by planned enrollment of the 57 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 in phase 3, reaches primary completion later than 18 of the 20 other live ones, and was the 78th registered.
260 studies on the registry are indexed under Ventricular Dysfunction, Left; 57 are open to participants now.
Browse Ventricular Dysfunction, Left studies →15 of the 84 studies in Ventricular Dysfunction, Left with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 45–60 · Women only
Bayer · Sites in United States, Argentina, Austria and 20 more countries
Ages up to 18
Mayo Clinic · Sites in United States
Ages 18+
Peerbridge Health, Inc · Sites in United States
Ages 18+ · Healthy volunteers
Sunnybrook Health Sciences Centre · Sites in United States, Austria, Brazil and 13 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Ventricular Dysfunction, Left studies recruiting now, 21 (55%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.
This study: 6 Months to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 18 · Phase 3 11 · Phase 4 8
First in 2001; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 111 is above the median of 100 across 151 interventional studies indexed under Ventricular Dysfunction, Left.
Median enrollment 87 across the 57 interventional studies, 307 across the 27 observational. Of the 58 that completed or were terminated, 29 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 84 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 5 studies filed under Ventricular Dysfunction, Left — fewer than ten, so there is no comparison to draw.
4 of the studies in Ventricular Dysfunction, Left with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04752293Wake Forest University Health SciencesPediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE) | 2026-12 |
| NCT05388032Tulane UniversitySodium Lowering Vascular Effects Trial | 2026-12-31 |
| NCT01114269Brigham and Women's HospitalPRE-DETERMINE Cohort Study | 2027-11 |
| NCT06699056Peerbridge Health, IncAI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor | 2027-11-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies in Ventricular Dysfunction, Left with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Researchers are looking for a better way to treat children who have heart failure with left ventricular systolic dysfunction (LVSD). Heart failure is a serious condition where the heart is unable to pump enough blood to meet the body's needs. This can lead to symptoms like shortness of breath, fatigue, and poor growth in children.
The study treatment, finerenone (also called BAY94-8862), works by blocking a protein involved in inflammation, scarring, and thickening of the heart and blood vessels. This may help the heart to pump blood more effectively. This is the first study to explore its use specifically for children with heart failure and LVSD.
The main purpose of this study is to learn if finerenone works to help the heart compared to placebo in children with heart failure and LVSD. For this, the researchers will collect and analyze data on the levels of a protein called NT-proBNP in the blood, which indicates heart stress, and monitor the safety of the treatment.
The study will include children with heart failure and LVSD aged from 6 months to less than 18 years. The study participants will be randomly assigned to one of two treatment groups. Based on their group, they will receive either finerenone or a placebo for a duration of 3 months. A placebo looks like a treatment but does not have any medicine in it. Throughout the study, all participants will continue to receive their standard heart failure treatments.
At the start of this study, the doctors will check each participant's medical history and current medications. If participants qualify for the treatment phase, they will undergo treatment for about 90 days. During this time, they will visit the study site at least 3 times. During these visits, the participants will:
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.
After the initial three-month study, eligible participants will have the option to join a nine-month open-label extension study where all will receive finerenone. Participants who choose not to enroll in the extension will have a follow-up visit 30 days after their last treatment.
The criteria were revised on the registry on Oct 15, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Elevated NT-pro BNP levels
Exclusion Criteria:
Serum/plasma potassium (based on local laboratory results):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive finerenone treatment.
Drug: Finerenone (Kerendia, BAY94-8862)
Participants will receive placebo to finerenone.
Drug: Placebo
Finerenone in different doses, treatment duration will be 90±3 days
Placebo to finerenone, treatment duration will be 90±3 days
Change in NT-proBNP levels
Time frame: From baseline to Day 90±3
Number of participants with treatment-emergent adverse events (TEAEs)
TEAEs will be mapped to Medical Dictionary for Regulatory Activities (MedDRA) terms
Time frame: From the start of study intervention to last study intervention (up to 93 days) + 3 days
Change in serum potassium levels
Time frame: From baseline to Day 90±3
Change in estimated glomerular filtration rate (eGFR)
Time frame: From baseline to Day 90±3
Change in systolic blood pressure (SBP)
Time frame: From baseline to Day 90±3
Change in left ventricular systolic function
Change measured by echocardiogram (%) from baseline to Day 90±3
Time frame: From baseline to Day 90±3
Total number of cardiovascular outcome events, including cardiovascular death, heart transplantation, and clinical worsening of heart failure
Time frame: From baseline to Day 90±3
Maximum observed finerenone concentration in plasma after multiple doses (Cmax, md)
Time frame: Pre-dose, post-dose (1.5-5 hours after intake of intervention), up to day 90±3
Area under the curve for finerenone concentration in plasma after multiple doses (AUCτ,md)
Time frame: Pre-dose, post-dose (1.5-5 hours after intake of intervention), up to day 90±3
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Showing the first 100 of 133 sites across 23 countries. Choose a country and city above to see the rest.
Plan to share: No — Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Nov 2029, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Finerenone
Ventricular Dysfunction, Left →